Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. Report for the third quarter of 2024

SZSIOct 30 00:00 · Announcements

vcanbio cell & gene engineering corp.,ltd. (600645.SH) released its performance for the first three quarters, with a net income of 0.134 billion yuan, a year-on-year increase of 0.76%.

vcanbio cell & gene engineering corp.,ltd. (600645.SH) disclosed its third quarter report for 2024, achieving operating income in the first three quarters...

Zhitong FinanceOct 29 18:13

Express News | Genoray's application for marketing approval for the new indication of recurrent or refractory large B-cell lymphoma has been accepted.

BreakingsSep 27 16:43

vcanbio cell & gene engineering corp.,ltd. (600645.SH): VUM02 injection receives drug clinical trial approval notice.

On September 9th, Vcanbio Cell & Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guangu Zhongyuan Pharmaceutical Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on September 9th, approving the use of VUM02 Injection for the treatment of systemic sclerosis. VUM02 Injection (Human Umbilical Cord Mesenchymal Stem Cell Injection) is a cryopreserved stem cell preparation independently developed by our company. It is a new drug prepared from selected healthy newborn umbilical cord tissues by in vitro separation, amplification, harvesting, and cryopreservation to obtain human umbilical cord mesenchymal stem cells (UC-MSCs). It is intended for clinical use.

Gelonghui FinanceSep 9 16:13

A-shares closing review: the Shanghai Composite Index fell more than 1% to 2736 points, with the sectors of cellular immunotherapy and medical services showing a rise.

On September 9th, China's August CPI and PPI were lower than expected, and the three major indices of A-shares opened lower and fluctuated lower after the opening, narrowing the decline by the end of the day, with the chinext price index turning red; as of the close, the Shanghai Composite Index fell 1.06% to 2765 points, hitting a new low since February 6th, the Shenzhen Component Index fell 0.83%, and the chinext price index rose 0.06%. Nearly 3100 stocks fell, with a total daily turnover of 518.6 billion yuan, a decrease of 24 billion yuan from the previous trading day. On the market, the medical sector has expanded opening-up pilot work, with sectors such as cellular immunotherapy and medical services rising, and stocks like Landfar Bio-medicine and Guanhao Biotech have hit the limit up; the assisted reproduction sector has also risen.

Gelonghui FinanceSep 9 15:02

The concept of genetic testing in A-shares is rising, and Guanhao Biotech has hit the limit.

Guanhao Biotech hit the limit up, Vcanbio Cell & Gene Engineering Corp.,Ltd. closed at the limit, Canature Health Technology, Nanjing Xinjiekou Department Store, Tellgen Corporation, Xi'an International Medical Investment all saw significant volume increase.

Gelonghui FinanceSep 9 09:55